Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers
pharmaceutical investing Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
Allied Critical Metals Closes Final Tranche of Over-Subscribed Non-Brokered Private Placement Upsized to $5.1 Million
